The anabolic wiki that shows its work.

Most steroid information on the internet is the same book quoted back and forth since the 1990s. This site only publishes what can be checked: every statement carries a grade and a receipt — the PubMed paper or the bioassay record it comes from.

How statements are graded

DATA MODEL CLAIM

DATA Published & linked

A peer-reviewed paper or a public bioassay record says exactly this. The receipt (PMID / assay ID) is linked inline, and the number on this page is the number in the source.

MODEL Reasoning, assumptions shown

Not directly measured, but derived from linked data. The assumptions are written out so you can reject the conclusion if you reject an assumption.

CLAIM Repeated everywhere, sourced nowhere

Standard gym/forum knowledge we could not find a source for. It stays on the page — visibly flagged — so you know which parts of the folklore are actually unverified.

Compounds — anabolics

Testosterone (enanthate)

The reference compound — the only AAS with blinded dose-ranging RCTs in healthy men: 50 → 600 mg/wk moved fat-free mass +0.8 → +8.1 kg. The dose ladder everyone else is extrapolated from.

Trenbolone

Zero modern human trials. The only human efficacy data: 1967, 17.5–35 mg/wk, nitrogen balance. No measured human half-life for any ester — every schedule ever posted is unsourced.

Drostanolone (Masteron)

A 1960s breast-cancer drug with three randomized trials at 300 mg/wk — and no measured receptor affinity, no half-life, no stacking study. The compound nobody measured.

Oxymetholone (Anadrol)

The only oral with a blinded 100 mg vs 150 mg RCT · a measured direct ERα agonism of 562 nM · and zero trials in healthy trained men.

Compounds — growth & bone

Somatropin (HGH)

The only compound here with dose-ranging trials measured to adult height — highest randomized pubertal dose 67 µg/kg/d. The curve saturates, and GH spends the growth-plate stem cells it grows you with.

Abaloparatide

A clean phase-3 fracture RCT (n=2,463) in postmenopausal osteoporosis — and a literature of exactly zero studies in anyone with open growth plates.

Compounds — ancillaries & support

Exemestane (Aromasin)

The entire male evidence base is one 10-day crossover of 12 healthy young men. No male data below 25 mg/day, none on any interval schedule — every micro-dose chart is untested extrapolation.

TUDCA

The default on-cycle liver supplement has never been studied alongside a steroid. What exists: UDCA's real cholestasis dose-response (13–15 mg/kg/d) and the stanozolol cholestasis registry.

NAC (N-acetylcysteine)

A genuine antidote with measured glutathione effects — and zero evidence for liver protection alongside AAS. Harmless and unproven here, not “liver protection.”

Melatonin

The one drug where the pharmacology argues for less: the sleep curve is flat from 0.3 mg, timing predicts response at r²=0.94 — and 20 mg is oncology dosing.

Creatine monohydrate

The best-evidenced item in any stack: 684 RCTs and no organ safety signal, settled saturation kinetics — and three independent null meta-analyses on bone.

Where the receipts come from

Literature: PubMed / Europe PMC. Receptor pharmacology: NCATS/NCGC qHTS confirmatory assays via ChEMBL / PubChem BioAssay. Every value lists the exact PMID or ChEMBL assay ID it was pulled from, with the pull date on the page.

Methods note: ChEMBL mirrors of qHTS sets include placeholder rows near each assay's maximum screened concentration (~44.7 µM) for inactive compounds — e.g. a “31.6 µM estradiol” row in an ERα agonist assay is biologically impossible and is treated as junk, not as data. Rows used on this site were sanity-checked against known reference ligands (e.g. diethylstilbestrol 1.0 nM in the same assay) before use.

What this site is not

Not medical advice, not a source to buy anything, and not written for anyone under 18. It is a harm-reduction reference for adults who are going to make their own decisions anyway: the least it can do is tell you which beliefs are load-bearing and which are folklore.